Delivery of multiple doses of medications

Details Delivery of multiple doses of medications Delivery of multiple doses of medications

1998-03-11

2003-10-21

Page, Thurman K. (Department: 1615)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Particulate form

C424S458000, C424S474000, C424S468000, C424S464000, C424S490000, C424S462000, C424S494000, C424S489000, C424S480000

Reexamination Certificate

active

06635284

ABSTRACT:

FIELD OF THE INVENTION
The present invention relates to improved dosing of medications. In particular, the present invention relates to improved dosing of a medication whereby two or more effective, time-separated doses may be provided by administration of a single dosage unit. The second, and any later, dose is time-delayed following administration. Based on predictable in vitro release times, the dosage forms can be formulated to deliver delayed doses in vivo at desired times.
The dosage forms and methods of the present invention are particularly suitable for the administration of methylphenidate hydrochloride, and especially for the administration of a single isomer, d-threo-methylphenidate hydrochloride.
The administration of dosage forms which contain an immediate dosage and a delayed second dosage provides for reduced abuse potential, improved convenience of administration, and better patient compliance, especially when methylphenidate is used to treat certain central nervous system disorders.
BACKGROUND OF THE INVENTION
Attention Deficit Disorder (ADD), a commonly diagnosed nervous system illness in children, is generally treated with methylphenidate hydrochloride (available commercially as, e.g., Ritalin®). Symptoms of ADD include distractibility and impulsivity. A related disorder, termed Attention Deficit Hyperactivity Disorder (ADHD), is further characterized by symptoms of hyperactivity, and is also treated with methylphenidate hydrochloride. Methylphenidate drugs have also been used to treat cognitive decline in patients with Acquired Immunodeficiency Syndrome (AIDS) or AIDS related conditions. See, e.g., Brown, G.,
Intl. J. Psych. Med.
25(1): 21-37 (1995); Holmes et al.,
J. Clin. Psychiatry
50: 5-8 (1989).
Methylphenidate exists as four separate optical isomers as follows:
wherein R
2
, is phenyl. Pharmaceutically acceptable salts are generally administered clinically. Other phenidate drugs, which also can be administered according to the invention, include those in which the methyl group in the above structures is replaced by C
2
-C
4
alkyl and R
2
is optionally substituted with C
1
-C
4
alkyl.
Clinically, the threo pair of enantiomers of methylphenidate hydrochloride is generally administered for the treatment of ADD and ADHD. The hydrochloride salt is commonly referred to simply as “methylphenidate”. Unless indicated otherwise, the term “methylphenidate” is used broadly herein to include methylphenidate and pharmaceutically acceptable salts thereof, including methylphenidate hydrochloride.
The threo racemate (pair of enantiomers) of methylphenidate is a mild central nervous system stimulant with pharmacological activity qualitatively similar to that of amphetamines. Undesirable side effects associated with the use of the dl-threo racemate of methylphenidate include anorexia, weight loss, insomnia, dizziness and dysphoria. Furthermore, the racemate, which is a Schedule II controlled substance, produces a euphoric effect when administered intravenously or through inhalation or ingestion, and thus carries a high potential for abuse.
Srinivas et al. studied the administration of dl-threo-, d-threo, and l-threo-methylphenidate to children suffering from ADHD, and reported that the pharmacodynamic activity of dl-threo-methylphenidate resides in the d-threo isomer (
Clin. Pharmacol, Ther
., 52: 561-568 (1992)). Therefore, while dl-threo-methylphenidate is generally used therapeutically, this racemate includes the I isomer which apparently makes no significant contribution to the pharmacological effectiveness of the drug, but likely contributes to the associated side effects. It is thus desirable to administer only the active d-threo form of the drug.
An additional problem is that children being treated with dl-threo methylphenidate must generally take one or more doses during the day. This creates a problem for school administrators who must store a controlled substance on school premises, with the associated risk that it may be stolen for illicit use. Furthermore, children may be traumatized by ridicule from peers when they must take medication at school.
Sustained release formulations of dl-threo methylphenidate have been developed, which provide for slow release of the drug over the course of the day. However, it has been observed that peak plasma concentrations of the drug are lower when sustained release formulations are used. In some studies, sustained release formulations of methylphenidate have been shown to have lower efficacy than conventional dosage forms.
There remains a need for methods for delivering methylphenidate with maximum effectiveness and minimal potential for abuse. Furthermore, it has been determined that there is a need for a dosage form which provides, in one administration, an initial release followed, at a predictable delay, by a second release, of maximally effective methylphenidate. This will eliminate the risk of theft or loss of the second dose, while minimizing undesirable side effects and maximizing ease of administration. The present invention is directed to these, as well as other, important ends.


REFERENCES:
patent: 2507631 (1950-05-01), Hartmann et al.
patent: 2957880 (1960-10-01), Rometsch
patent: 4137300 (1979-01-01), Sheth et al.
patent: 4794001 (1988-12-01), Mehta et al.
patent: 4968505 (1990-11-01), Okada et al.
patent: 4992445 (1991-02-01), Lawter et al.
patent: 5104899 (1992-04-01), Young et al.
patent: 5114946 (1992-05-01), Lawter et al.
patent: 5133974 (1992-07-01), Paradissis et al.
patent: 5156850 (1992-10-01), Wong et al.
patent: 5202128 (1993-04-01), Morella et al.
patent: 5217718 (1993-06-01), Colley et al.
patent: 5223265 (1993-06-01), Wong
patent: 5232705 (1993-08-01), Wong et al.
patent: 5283193 (1994-02-01), Yamamoto et al.
patent: 5284769 (1994-02-01), Evans et al.
patent: 5308348 (1994-05-01), Balaban et al.
patent: 5326570 (1994-07-01), Rudnic et al.
patent: 5331000 (1994-07-01), Young et al.
patent: 5362755 (1994-11-01), Barberich et al.
patent: 5375693 (1994-12-01), Woosley et al.
patent: 5449743 (1995-09-01), Kobayashi et al.
patent: 5478573 (1995-12-01), Eichel et al.
patent: 5500227 (1996-03-01), Oshlack et al.
patent: 5512293 (1996-04-01), Landrau et al.
patent: 5580578 (1996-12-01), Oshlack et al.
patent: 5593694 (1997-01-01), Hayashida et al.
patent: 5639476 (1997-06-01), Oshlack et al.
patent: 5672360 (1997-09-01), Sackler et al.
patent: 5874090 (1999-02-01), Baker et al.
patent: 1297368 (1992-03-01), None
patent: 2 635 460 (1994-09-01), None
patent: WO 93/05769 (1993-04-01), None
patent: WO 97/03671 (1997-02-01), None
patent: WO 97/03672 (1997-02-01), None
patent: WO 97/03673 (1997-02-01), None
patent: WO 98/06380 (1998-02-01), None
patent: WO 98/14168 (1998-04-01), None
patent: WO 98/23263 (1998-06-01), None
patent: WO 99/62496 (1999-09-01), None
Angrist et al.,J. Clin. Psychopharm.,1992, 12(4), 268-272.
Barkley et al.,Pediatrics,1990, 86(2), 184-192.
Barkley et al.,Pediatrics,1991, 87(4), 519-531.
Golinko,Prog. Neuro-Psychopharm. Biol. Psychiat.,1984, 8, 1-8.
Holmes et al., “Psychostimulant Response in Aids-Related Complex Patients”,J. Clin. Psychiatry,1989, 50(1), 5-8 (Biosis Abstract No. 87129969).
Srinivas et al., “Enantioselective Pharmacolinetics and Pharmacodynamics of Racemic Threo-Methylphenidate in Children with Attention Deficit Hyperactivity Disorder”,Clin. Pharmacol.,1992, 52(5), 561-568 (Biosis Abstract No. 95066168).
Aoyama et al., “Pharmacolinetics and pharmacodynamics of (+)-threo-methylphenidate enantiomer in patients with hypersomnia”,Clin. Phamacol. Ther.,1994, 55(3), 270-276.
Bowden et al., “Reactions of Carbonyl Compounds in Basic Solutions the Alkaline Hydrolysis of N-Methyl, N-Phenyl, and Bicyclo Lactams Penicillins, and N-Aklyl-N-methylacetamides”,J. Chem. Soc. Perkin Trans.,1990, 12, 2111-2116.
Brown, “Pharmacological Action and Drug Development”,Chirality in Drug Design and Synthesis,Academic Press Inc., 1990, 4-7.
Brown G., “The Use of Methylphenidate for Cognitive Decline Associated with HIV Disease”,Int'l J. Psychiatry Med.,1995, 25(1), 21-37.
Core

Affiliated with

Also associated with

Rating

Delivery of multiple doses of medications does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Delivery of multiple doses of medications, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Delivery of multiple doses of medications will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3158632